The major goal of this study was to develop and test metformin sustained release tablets employing fenugreek seed mucilage (FSM) as a new binder, as opposed to standard polymers such as xanthan gum and HPMC. The study shows how FSM provides sustained medication release while keeping metformin physicochemical characteristics. The sustained-release matrix tablets were made on a laboratory scale utilizing the wet granulation process. 5 batches were created, each with varying quantities of fenugreek seed mucilage, xanthan gum, and HPMC. To examine the tablet's physical properties and consistency, different criteria such as thickness, hardness, weight variation, and content homogeneity were measured. FTIR tests were performed to determine the compatibility of metformin and the polymers employed. The results showed no incompatibility, indicating that the novel excipient, FSM was not affecting the drug's physicochemical qualities. The in-vitro drug dissolution investigation was conducted utilizing a USP type-II paddle apparatus to quantify the drug release rate from dosage forms and to assess thepolymers' efficacy in retarding drug release. The study discovered that raising the concentration ofthe matrix ingredient reduced the medication release rate. Among the formulations, the combination of FSM with HPMC (MS1) resulted in 95% drug release, FSM with xanthan gum achieved 96% drug release, and the MS4 formulation had the greatest drug release rate. Finally, the study showed that fenugreek seed mucilage and xanthan gum effectively develop metformin continuous-release matrix tablets. Lower concentrations of these polymers were more suited and effective, resulting in sustained drug release. This study demonstrates the potential of fenugreek seed mucilage as a novel and effective binder in sustained-release formulations.